PACB — Pacific Biosciences of Californ

Is PACB overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of November 17, 2026

Pacific Biosciences of Californ (PACB) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $1.84. The rating moved from Strong Oversold to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Pacific Biosciences of Californ (PACB) offers a technically differentiated long‑read sequencing platform with meaningful scientific advantages and a large addressable market, but near‑term fundamentals are clouded by revenue variability, cash‑burn dynamics, and potential dilution pressure. Broader sector flows that favor large-cap defensive healthcare reduce some investor focus on mid-cap sequencing, while adoption and commercial execution remain the primary drivers of upside. The balance of strong technology readthroughs versus financing and competition risks suggests limited near-term directional conviction until clearer evidence of consistent revenue growth and cash runway appears.

Key factors

  • Differentiated long‑read sequencing technology (HiFi accuracy) with clear scientific advantages for complex genome and structural-variant applications
  • Addressable end markets across research, clinical genomics, and biopharma applications with secular demand for higher‑accuracy long reads
  • Recent revenue and order variability that create uncertainty in near‑term growth trajectory and guidance visibility
  • Competitive pressure from larger incumbents (Illumina) and fast-moving rivals (Oxford Nanopore) on price, channels, and scale
  • Macro/sector backdrop favoring growth exposure, which can support interest in sequencing-related names if execution improves
  • Industry-wide note on convertible-debt/dilution pressures in diagnostics/biotech that could increase financing risk for mid-cap players

Risks

  • Elevated cash burn and limited liquidity leading to the need for near-term financing or dilutive capital raises
  • Share dilution and investor dilution from convertible debt or equity financings, pressuring per-share value
  • Intensifying competition on price and channel relationships from larger sequencing providers and alternative long-read platforms
  • Execution risk on commercial expansion, instrument placements, consumables attach rate, and customer adoption timelines
  • Revenue cyclicality and backlog volatility tied to large institutional orders that can swing reported results
  • Supply chain or manufacturing disruptions that could delay instrument shipments and consumables revenue
  • Limited social/research sentiment data available increases uncertainty around retail-driven momentum

See today's live rating, score and targets

Members see the live hourly rating for PACB — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.